Business Context and Reporting Period
This Form 8-K filing by Calidi Biotherapeutics, Inc. (CLDI) reports corporate governance changes effective August 16, 2024. The Company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on board composition changes.
Material Changes
- Director Departure: Mr. George Ng informed the Board on August 16, 2024, that he intends to allow his term as a Director to expire at the 2024 annual shareholder meeting to focus on outside professional commitments.
- Continued Relationship: Mr. Ng will maintain a strategic advisory and consultancy relationship with the Company following his departure from the Board.
- Board Size Reduction: The Board reduced its size from six to five directors by eliminating the Class I vacancy expected from Mr. Ng's term expiration.
- No Disagreement: The filing explicitly states that Mr. Ng's decision did not result from any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of new risks or contingencies. The event is described as a routine governance adjustment permitted by the Company's Bylaws.
Key Facts for Investor Verification
- Verify the exact date of the 2024 annual shareholder meeting to confirm the effective date of the Board size reduction.
- Confirm the terms of the new strategic advisory and consultancy agreement with Mr. Ng, including any compensation details not disclosed in this summary.
- Review the Company's upcoming proxy statement for details on the remaining Board composition and any new director nominations.